Increased CCL2/CCR2 axis in MYC/BCL2 double-expressor DLBCL promotes tumor progression by increasing M2 macrophages
RNA-seq (gene expression) · human · 28 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Topic
- Diffuse large B-cell lymphomaThis series is part of our curated briefing on it.
- Samples
- 28 samples: 28 samples, each with a distinct title — no replicated groupsGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- Increased CCL2/CCR2 axis promotes tumor progression by increasing M2 macrophages in MYC/BCL2 double-expressor DLBCLBlood advances · 2024
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE252690_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1062058 and SRA study SRP482322. Searching any of these in the dataset finder brings you back here.
Any grouping that defines a comparison lives in the sample characteristics, which GEO records separately from the titles.
How we read this: Read from 28 sample titles: 28 distinct titles with little repetition. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM8005200 DLBCL_01, DE
- GSM8005201 DLBCL_02, nonDE
- GSM8005202 DLBCL_03, DE
- GSM8005203 DLBCL_04, DE
- GSM8005204 DLBCL_05, DE
- GSM8005205 DLBCL_06, nonDE
- GSM8005206 DLBCL_07, DE
- GSM8005207 DLBCL_08, nonDE
- GSM8005208 DLBCL_09, DE
- GSM8005209 DLBCL_10, nonDE
- GSM8005210 DLBCL_11, nonDE
- GSM8005211 DLBCL_12, DE
- GSM8005212 DLBCL_13, nonDE
- GSM8005213 DLBCL_14, DE
- GSM8005214 DLBCL_15, nonDE
- GSM8005215 DLBCL_16, nonDE
- GSM8005216 DLBCL_17, DE
- GSM8005217 DLBCL_18, nonDE
- GSM8005218 DLBCL_19, nonDE
- GSM8005219 DLBCL_20, nonDE
- GSM8005220 DLBCL_21, nonDE
- GSM8005221 DLBCL_22, DE
- GSM8005222 DLBCL_23, DE
- GSM8005223 DLBCL_24, nonDE
- GSM8005224 DLBCL_25, DE
- GSM8005225 DLBCL_26, DE
- GSM8005226 DLBCL_27, DE
- GSM8005227 DLBCL_28, nonDE
- GSE211451 Targeting AURKA to induce synthetic lethality in CREBBP-deficient DLBCL via attenuation of MYC expression 8 samples same disease briefing · shares dlbcl, myc
- GSE232330 Targeting AURKA to induce synthetic lethality in CREBBP-deficient DLBCL via attenuation of MYC expression 3 samples same disease briefing · shares dlbcl, myc
- GSE231624 (1) Effect of KLHL6 loss on the transcriptome in DLBCL upon NOTCH ligand stimulation. (2) Effect of KLHL6 and NOTCH2 loss on the transcriptome in DLBCL. (3) Effect of DLBCL-associated NOTCH2 mutants on the transcriptome in DLBCL. 48 samples same disease briefing · shares dlbcl
- GSE277665 DOT1L and EZH2 cooperatively repress PRC2 targets to maintain the GC B cell identity in DLBCL [RNA-seq] 48 samples same disease briefing · shares dlbcl
- GSE224867 RNA-seq analysis of DLBCL cell lines in response to chemotherapy 36 samples same disease briefing · shares dlbcl
- GSE280799 Expression Data from DLBCL Cell Line U2932 (Parental, CDC-Treated, and CDC-Resistant) and 8 DLBCL Patient Samples (5 High CDC-Sensitive, 3 Low CDC-Sensitive) 20 samples same disease briefing · shares dlbcl
- GSE228738 HDAC7 is essential in early pre-germinal center formation and its deregulation is associated with DLBCL 12 samples same disease briefing · shares dlbcl
- GSE242115 Morusinol is a Potent Therapeutic Agent Against DLBCL II 12 samples same disease briefing · shares dlbcl
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.